Recognition and Management of Hereditary Breast Cancer Syndromes
Open Access
- 1 February 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 9 (1), 13-24
- https://doi.org/10.1634/theoncologist.9-1-13
Abstract
Clinicians should recognize the genetic syndromes that predispose to the development of breast cancer so that patients may be afforded the opportunity to have genetic testing to assist them and their family members in making medical management decisions. Approximately 80%–90% of hereditary breast cancer cases are caused by mutations in the BRCA1 and BRCA2 genes. Other important clinical genetic predispositions include Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome, and ataxia-telangiectasia. The key to identifying women who are at risk for a hereditary breast cancer lies in obtaining an adequate, three-generation family history, including ethnic background. For unaffected women, breast cancer risks can be estimated using the quantitative models of Gail and Claus, but there are limitations to these models. Other quantitative models predict the likelihood that a patient is carrying a mutated gene. Genetic testing is available at selected laboratories for each of the hereditary syndromes described, and there are three possible outcomes to testing. These outcomes and their management implications are described in detail. Clinical management options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic surgery. Application of these principles can reduce morbidity in women with genetic predispositions to breast cancer.Keywords
This publication has 72 references indexed in Scilit:
- American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer SusceptibilityJournal of Clinical Oncology, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerThe Journal of Pathology, 2001
- Male breast cancer in Cowden syndrome patients with germline PTEN mutationsJournal of Medical Genetics, 2001
- Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer FamiliesAmerican Journal of Human Genetics, 1998
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined AnnuallyJNCI Journal of the National Cancer Institute, 1989
- Increased Risk of Cancer in the Peutz–Jeghers SyndromeNew England Journal of Medicine, 1987
- Breast and Other Cancers in Families with Ataxia-TelangiectasiaNew England Journal of Medicine, 1987